GLP-1 drugs and disease prevention: what the evidence actually supports

What's this video probably claiming?

Based on the caption, @glpwithelene appears to be arguing that GLP-1 receptor agonists, drugs like semaglutide and tirzepatide, are on the verge of reshaping outcomes across a wide range of conditions beyond weight loss and type 2 diabetes. The list reads like a greatest-hits of emerging GLP-1 research: reduced diabetes incidence, PCOS fertility improvements, cancer risk reduction, NASH/NAFLD reversal, Alzheimer's prevention, and kidney protection. The truncated caption ending with "And mayb" suggests even more is coming. This creator is almost certainly framing GLP-1 drugs as a generational medical shift, and to be fair, the research does support parts of that framing. But a caption stitching together phase 2 trials, observational data, and early mechanistic studies into one breathless list deserves scrutiny. The hashtag "prediction" is doing a lot of work here.

What does the science actually show?

Some of this is more solid than it looks on TikTok, and some of it is far earlier-stage than the caption implies. On diabetes prevention: the SELECT trial (Lincoff et al., 2023, NEJM) showed semaglutide 2.4mg reduced major cardiovascular events by 20% in non-diabetic adults with obesity, and secondary analyses suggest meaningful metabolic benefits. On PCOS: small RCTs, including Elkind-Hirsch et al. (2022, Journal of Clinical Endocrinology), show GLP-1 agonists improving insulin sensitivity and menstrual regularity, but IVF outcome data is preliminary at best. On NASH: the ESSENCE trial for semaglutide in MASH (metabolic-associated steatohepatitis) showed 62.9% histological improvement versus 34.3% placebo at 72 weeks (Newsome et al., 2023, NEJM). On kidney disease: the FLOW trial (Perkovic et al., 2024, NEJM) showed semaglutide reduced kidney disease progression by 24% in type 2 diabetes patients. On cancer: population-level observational data from Yeo et al. (2024, JAMA Oncology) suggests reduced obesity-related cancer incidence, but causality is not established. On Alzheimer's: it is mechanistic and early-phase only.

Where does the social media noise diverge from clinical reality?

The core problem with this type of caption is that it presents a spectrum of evidence as if it were a uniform body of proof. The FLOW kidney trial enrolled patients with existing diabetic kidney disease and type 2 diabetes, not the general public taking Wegovy for weight loss. Extrapolating that to "improved kidney health" for all GLP-1 users is a stretch. The Alzheimer's framing, leaning on the "type 3 diabetes" hypothesis, is particularly speculative. A Danish registry study (Norgaard et al., 2022, Alzheimer's and Dementia) found lower dementia incidence in GLP-1 users, but this is observational and confounded heavily by metabolic health differences at baseline. The PCOS-to-fewer-IVF-journeys claim is the weakest link: there are no large RCTs confirming GLP-1 use meaningfully reduces IVF utilization rates. Framing a plausible hypothesis as a near-certainty is how TikTok health content misleads even well-meaning audiences.

What should you actually know?

GLP-1 receptor agonists are genuinely interesting drugs with an expanding evidence base, and the excitement is not entirely manufactured. The liver disease data from the ESSENCE trial is real and clinically meaningful. The cardiovascular and kidney data from SELECT and FLOW are from well-designed, large RCTs. But "real and clinically meaningful" in a specific trial population is different from "this drug will prevent cancer and Alzheimer's in people using it for weight loss." If you are currently on semaglutide or tirzepatide, the legitimate reason to feel encouraged is the metabolic and cardiovascular data. The cancer and neurological findings are hypothesis-generating, not practice-changing. Doses matter, populations matter, and duration of follow-up matters. None of that fits in a TikTok caption. Talk to a clinician who has read these trials, not just the headlines.